Study of CM313 for treating pemphigus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new medicine called CM313 for people with moderate to severe pemphigus, a condition that causes painful blisters on the skin and mouth. The goal is to see if CM313 can help reduce these blisters and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with moderate to severe pemphigus (either pemphigus vulgaris or foliaceus).
- You have skin blisters that break easily, or sores that don't heal, or blisters in your mouth or other moist areas.
- You have a positive Nikolsky's sign (a test where rubbing skin causes it to peel).
- You are not pregnant, planning to become pregnant, or breastfeeding.
- You have not had certain treatments (like IV cyclophosphamide, plasma exchange, or immunoadsorption) in the last 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called B007 for people with pemphigus, a rare autoimmune disease that causes painful blisters on the skin and inside the mouth. It aims to see if B007 can control the disease and allow patients to reduce other treatments.
This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.
This study tests a new drug called CM313 (an antibody that targets a protein on immune cells) for treating pemphigus, a condition that causes painful blisters on the skin and mouth. The goal is to see if it can reduce blisters and improve quality of life, especially for people who haven't responded well to other treatments.
This study tests a new drug called CM336 for people with autoimmune blistering diseases. The drug is designed to calm the immune system and reduce blistering, aiming to improve skin health.
This study tests whether a steroid mouthwash and/or light therapy (photobiomodulation) can help heal painful mouth sores caused by pemphigus vulgaris, an autoimmune disease that damages the inside of the mouth and skin.
This Phase 1/2 trial tests the safety and dosing of genetically modified immune cells made from your own blood (autologous CAR T or related cells) for active pemphigus vulgaris. It may help control disease that is not adequately managed with standard medicines.
Hear when a new Pemphigus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.